Quality of life assessment in survivors of breast cancer

被引:19
作者
Wani, Shaqul Qamar [1 ]
Khan, Talib [2 ]
Teeli, Ashraf M. [3 ]
Khan, Nazir A. [3 ]
Wani, Saiful Yamin [4 ]
Ashfaq-ul-Hassan [5 ]
机构
[1] Govt Med Coll & Associated Hosp, Dept Radiat Oncol, Srinagar 190010, Jammu & Kashmir, India
[2] Govt Med Coll & Associated Hosp, Dept Anaesthesiol Intens Care & Pain Management, Srinagar 190010, Jammu & Kashmir, India
[3] Sherikashmir Inst Med Sci, Dept Radiat Oncol, Srinagar, Jammu & Kashmir, India
[4] Police Lines, Dept Med Doctors, Baramullah, JK, India
[5] Sherikashmir Inst Med Sci, Coll Med, Dept Clin Anat, Srinagar, Jammu & Kashmir, India
关键词
Breast cancer; european organization for research and treatment of cancer; health-related quality of life; EUROPEAN-ORGANIZATION; LONG-TERM; THERAPY; WOMEN; QUESTIONNAIRE; CHEMOTHERAPY;
D O I
10.4103/0973-1482.98986
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim was to assess the health-related quality of life (HRQOL) and its temporal variation at first visit and subsequent visits among breast cancer patients. Design and Setting: The prospective study was carried out in Outpatient Department of Radiation Oncology, University Teaching and Tertiary Referral Hospital. Material and Methods: After clearance from the ethical committee and EORTC group, 81 surgically treated female breast cancer patients referred to the Outpatient Department of Radiation Oncology for chemoradiation and hormonal therapy were included in the study after informed written consent, irrespective of the age and stage of disease. The patients were interviewed as per the EORTC QLQ-C30 Questionnaire module at four levels at the first visit and at subsequent follow-up visits at 6, 12, and 24 months, respectively, and are still on follow-up. Statistical Analysis: The data collected were expressed as mean/raw score (RS), standard deviation (SD), and percent mean/scale score expressed on the linear transformation scale, derived as per the calculations and equations of the EORTC QLQ-C30 Scoring Manual. Intragroup comparison (IGC) was done at four levels/visits, a, b, c and d. A P-value of < 0.05 was considered significant. Results: The mean age at presentation was 46.6 10.2 years. The study showed that the physical functioning, role functioning, cognitive functioning, emotional functioning, social functioning, global health status, and symptomatology showed statistically significant improvement over time (P < 0.001). Conclusion: The survivors of female breast cancer over the long-term follow-up showed significant improvement and coping mechanisms involved in a majority of HRQOL parameters.
引用
收藏
页码:272 / 276
页数:5
相关论文
共 26 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Impact of cancer occurrence on health-related quality of life: A longitudinal pre-post assessment [J].
Boini S. ;
Briançon S. ;
Guillemin F. ;
Galan P. ;
Hercberg S. .
Health and Quality of Life Outcomes, 2 (1)
[3]   The cancer patient and quality of life [J].
Bottomley, A .
ONCOLOGIST, 2002, 7 (02) :120-125
[4]   Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group study 9401 [J].
Brandberg, Y ;
Michelson, H ;
Nilsson, B ;
Bolund, C ;
Erikstein, B ;
Hietanen, P ;
Kaasa, S ;
Nilsson, J ;
Wiklund, T ;
Wilking, N ;
Bergh, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3659-3664
[5]   MEASURING QUALITY OF LIFE IN CANCER-PATIENTS [J].
DONOVAN, K ;
SANSONFISHER, RW ;
REDMAN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (07) :959-968
[6]  
Engel Jutta, 2004, Breast J, V10, P223, DOI 10.1111/j.1075-122X.2004.21323.x
[7]  
Fakhro A E, 1999, East Mediterr Health J, V5, P430
[8]  
Fayers P., 2001, European organisation for research and treatment of cancer, V3rd
[9]  
Feher S, 1999, PSYCHO-ONCOL, V8, P408, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<408::AID-PON409>3.0.CO
[10]  
2-5